Your browser doesn't support javascript.
loading
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.
Leal, Ana S; Moerland, Jessica A; Zhang, Di; Carapellucci, Sarah; Lockwood, Beth; Krieger-Burke, Teresa; Aleiwi, Bilal; Ellsworth, Edmund; Liby, Karen T.
Afiliação
  • Leal AS; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Moerland JA; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Zhang D; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Carapellucci S; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Lockwood B; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Krieger-Burke T; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Aleiwi B; In Vivo Facility, Michigan State University, East Lansing, MI 48824, USA.
  • Ellsworth E; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA.
  • Liby KT; Medicinal Chemistry Facility, Michigan State University, East Lansing, MI 48824, USA.
Cancers (Basel) ; 13(19)2021 Oct 06.
Article em En | MEDLINE | ID: mdl-34638488
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article